Privo Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Privo Technologies is a private, pre-revenue biotech founded in 2019 and based in Cambridge, MA. The company's core asset is the PRV™ platform, a nanotechnology-enabled system for the localized delivery of chemotherapeutics (e.g., cisplatin) via patches, hydrogels, and injectables. Its pipeline is advanced, with PRV111 for oral carcinoma in situ in Phase 3, PRV211 for intraoperative use in Phase 1/2, and PRV131 as an intratumoral injectable in early clinical studies, all supported by over $20M in non-dilutive funding from U.S. government agencies.

Oncology

Technology Platform

The PRV™ platform is a nanotechnology-enabled drug delivery system for the locoregional administration of therapeutics. It utilizes various formulations (patches, hydrogels, injectables) to deliver high concentrations of drugs like cisplatin directly to tumor sites, aiming to maximize efficacy while minimizing systemic toxicity.

Opportunities

Privo has a first-mover opportunity to establish a non-surgical standard of care for early-stage oral cancer with PRV111, addressing a significant unmet need.

The adaptable PRV platform also allows for expansion into other solid tumor indications and delivery methods, creating a broad pipeline from a single core technology.

Risk Factors

Key risks include failure in late-stage clinical trials, challenges in changing clinical practice away from surgery, and the need to secure substantial additional funding to complete Phase 3 development and commercialization.

As a novel therapeutic approach, market adoption and reimbursement could also pose hurdles.

Competitive Landscape

Privo's primary competition in oral CIS is surgery, as no approved non-surgical drug therapies exist. For intraoperative and intratumoral chemotherapy, competition includes off-label use of existing chemotherapies and other companies developing localized delivery systems. Privo's differentiation lies in its proprietary nano-engineered formulations designed for sustained, targeted release.

More companies in Oncology (General) →More companies in United States →